Program
Digoxin
Also written as “digoxin”, “ZT002 injection, rosuvastatin, digoxin” and “Digoxin (0.25mg)”.
Its studies are mostly in Obesity · Neoplasms · Thalassemia · Carcinoma, Non-Small-Cell Lung · Liver Cirrhosis, led by 25 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 90 open or running | phase 1since Jun 1, 2010 | Jun 1, 2010 | none ahead |
| AstraZeneca | 30 open or running | phase 1since Jul 8, 2008 | Jul 8, 2008 | none ahead |
| Bristol-Myers Squibb | 30 open or running | phase 1since Oct 9, 2014 | Oct 9, 2014 | none ahead |
| Astellas Pharma | 20 open or running | phase 1since Apr 29, 2014 | Apr 29, 2014 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 1since Mar 28, 2008 | Mar 28, 2008 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 1since Jan 9, 2013 | Jan 9, 2013 | none ahead |
| Johnson & Johnson | 20 open or running | phase 1since Jan 20, 2011 | Jan 20, 2011 | none ahead |
| Merck | 20 open or running | phase 1since Aug 26, 2024 | Aug 26, 2024 | none ahead |
| Sanofi | 20 open or running | phase 1since May 19, 2011 | May 19, 2011 | none ahead |
| AbbVie | 10 open or running | phase 1since Feb 3, 2016 | Feb 3, 2016 | none ahead |
| Beijing QL Biopharmaceutical | 11 open or running | phase 1since Apr 20, 2026 | Apr 20, 2026 | Dec 5, 2026phase 1 · NCT07550816 |
| Biogen | 10 open or running | phase 1since May 11, 2012 | May 11, 2012 | none ahead |
| cmp-development-llc | 10 open or running | phase 1since Feb 16, 2019 | Feb 16, 2019 | none ahead |
| CSL | 10 open or running | phase 1since Nov 16, 2011 | Nov 16, 2011 | none ahead |
| Daiichi Sankyo | 10 open or running | phase 1since Jan 4, 2012 | Jan 4, 2012 | none ahead |
| Eisai | 10 open or running | phase 1since Jan 23, 2014 | Jan 23, 2014 | none ahead |
| Eli Lilly | 10 open or running | phase 1since Dec 16, 2023 | Dec 16, 2023 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since Mar 17, 2020 | Mar 17, 2020 | none ahead |
| Maruho | 10 open or running | phase 2since Dec 19, 2014 | Dec 19, 2014 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Sep 23, 2021 | Sep 23, 2021 | none ahead |
| Novo Nordisk | 10 open or running | phase 1since Feb 3, 2025 | Feb 3, 2025 | none ahead |
| Pfizer | 10 open or running | phase 1since Jan 27, 2009 | Jan 27, 2009 | none ahead |
| pharmaand | 10 open or running | phase 1since Mar 30, 2016 | Mar 30, 2016 | none ahead |
| Puma Biotechnology | 10 open or running | phase 1since Mar 11, 2009 | Mar 11, 2009 | none ahead |
| Takeda | 10 open or running | phase 1since Apr 20, 2016 | Apr 20, 2016 | none ahead |
Also a collaborator on its studies: parexel, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene and medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Mar 28, 2008.
- Sep 17, 2019Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT04094519 · 24 enrolled · Moldova, Republic of
- Jan 14, 2020Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04231435 · 24 enrolled · United States
- Mar 17, 2020Jiangsu HengRui Medicine's first study: phase 1 study in Advanced Solid TumorNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04322552 · 18 enrolled · China
- Oct 15, 2020Phase 1 study in HealthyBoehringer Ingelheim · NCT04590937 · 15 enrolled · Germany
- Sep 23, 2021Merck KGaA, Darmstadt, Germany's first study: phase 1 study in HealthyNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05064488 · 40 enrolled · Germany
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741372 · 28 enrolled · Germany
- Mar 3, 2023Phase 1 study in Healthy Male SubjectsAstraZeneca · NCT05768360 · 6 enrolled · Germany
- Dec 16, 2023Eli Lilly's first study: phase 1 study in ObesityNew to Eli LillyEli Lilly · NCT06186622 · 50 enrolled · United States
- Aug 26, 2024Merck's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to MerckMerck · NCT06575933 · 28 enrolled · United States
- Oct 1, 2024Phase 1 study in HealthyMerck · NCT06625827 · 24 enrolled · United States
- Nov 5, 2024Phase 1 study in Healthy ParticipantsHoffmann-La Roche · NCT06677957 · 19 enrolled · United States
- Feb 3, 2025Novo Nordisk's first study: phase 1 study in ThalassemiaNew to Novo NordiskNovo Nordisk · NCT06813924 · 37 enrolled · United States
- Aug 5, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07118215 · 62 enrolled · United States
- Apr 20, 2026Beijing QL Biopharmaceutical's first study: phase 1 study in OverweightNew to Beijing QL BiopharmaceuticalBeijing QL Biopharmaceutical · NCT07550816 · 60 enrolled · China
Ahead
- Dec 5, 2026Primary completion: phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07550816
TargetBeta
“Sodium/potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same 8 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Istaroximerule | windtree-therapeutics | phase 3 | 8 |
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07550816Overweight · China | 1 | Active, not recruiting | Beijing QL Biopharmaceutical | Dec 5, 2026 | 60 |
| NCT07118215Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Jun 25, 2026 | 62 |
| NCT06813924Thalassemia · United States | 1 | Completed | Novo Nordisk | May 27, 2025 | 37 |
| NCT06677957Healthy Participants · United States | 1 | Completed | Hoffmann-La Roche | Dec 30, 2024 | 19 |
| NCT06625827Healthy · United States | 1 | Completed | Merck | Jan 22, 2024 | 24 |
| NCT06575933Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Merck | Oct 28, 2024 | 28 |
| NCT06186622Obesity · United States | 1 | Completed | Eli Lilly | Jul 10, 2024 | 50 |
| NCT05768360Healthy Male Subjects · Germany | 1 | Completed | AstraZeneca | Jun 24, 2023 | 6 |
| NCT05741372Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Dec 18, 2024 | 28 |
| NCT05064488Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Dec 10, 2021 | 40 |
| NCT04590937Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 11, 2021 | 15 |
| NCT04322552Advanced Solid Tumor · China | 1 | Completed | Jiangsu HengRui Medicine | Apr 3, 2021 | 18 |
| NCT04231435Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2020 | 24 |
| NCT04094519Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Astellas Pharma | Dec 27, 2020 | 24 |
| NCT03909529Drug Drug Interaction · India | 1 | Completed | cmp-development-llc | Apr 19, 2019 | 28 |
| NCT03307252Healthy · Germany | 1 | Completed | Boehringer Ingelheim | May 2, 2018 | 45 |
| NCT02854527Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 11, 2016 | 30 |
| NCT02775240Cytomegalovirus (CMV) · United States | 1 | Completed | Takeda | Sep 12, 2016 | 18 |
| NCT02740712Neoplasms · Poland | 1 | Completed | pharmaand | Mar 2017 | 17 |
| NCT02685462Healthy · United States | 1 | Completed | AbbVie | Feb 23, 2016 | 36 |
| NCT02345304Healthy · Germany | 1 | Withdrawn | Boehringer Ingelheim | Apr 2015 | 0 |
| NCT02333643Cutaneous Warts · Netherlands | 2 | Completed | Maruho | Aug 2015 | 81 |
| NCT02262520N/A - Healthy Subjects | 1 | Completed | Bristol-Myers Squibb | Mar 2006 | 24 |
| NCT02231931Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 1, 2015 | 24 |
| NCT02171052Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 24 |
| NCT02127034Healthy Subjects · Germany | 1 | Completed | Astellas Pharma | Jun 2014 | 26 |
| NCT02055703Healthy Subjects · United States | 1 | Completed | Eisai | Apr 2014 | 195 |
| NCT01765569Melanoma · Belarus, Israel, Korea, Republic of and more | 1 | Completed | Hoffmann-La Roche | Jun 2014 | 29 |
| NCT01598363Healthy Volunteers · United States | 1 | Completed | Biogen | Jul 31, 2012 | 32 |
| NCT01561781Healthy Volunteers · United States | 1 | Completed | Sanofi | Jul 2012 | 14 |
| NCT01583036Epilepsy · United States | 1 | Completed | GlaxoSmithKline | Apr 17, 2012 | 30 |
| NCT01517399Neoplasms · United States | 1 | Completed | Daiichi Sankyo | Aug 2013 | 28 |
| NCT01519128Acquired Immunodeficiency Syndrome · Belgium | 1 | Completed | Johnson & Johnson | Apr 2012 | 22 |
| NCT01477411Drug Interaction Potentiation · United States | 1 | Completed | CSL | Jan 2012 | 42 |
| NCT01357811Healthy Volunteer · United States | 1 | Completed | Sanofi | Nov 2011 | 28 |
| NCT01306175Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Apr 2011 | 20 |
| NCT01288742Hepatitis C | 1 | Completed | Johnson & Johnson | May 2011 | 33 |
| NCT01134965Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2010 | 24 |
| NCT00904176Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Aug 2009 | 30 |
| NCT00860223Healthy · United States | 1 | Completed | Puma Biotechnology | Apr 2009 | 27 |
| NCT00831506Alzheimer Disease · United States | 1 | Completed | Pfizer | May 2009 | 12 |
| NCT00712465Atrial Fibrillation · Sweden | 1 | Completed | AstraZeneca | Nov 2008 | 18 |
| NCT00650910Breast Neoplasms · United States, Canada, Korea, Republic of | 1 | Completed | GlaxoSmithKline | Jul 10, 2009 | 17 |
How it is read
Names in the registry
- “Digoxin”, 33 entries
- “digoxin”, 6 entries
- “ZT002 injection, rosuvastatin, digoxin”, 1 entry
- “Digoxin (0.25mg)”, 1 entry
- “Lenoxin®”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Neoplasms, 2 studies
- Thalassemia, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.